Key Takeaway: 4D Molecular Therapeutics announced that its gene therapy for wet age-related macular degeneration (AMD) has resulted in reduced reliance on Eylea among patients. The company is preparing for pivotal studies to further evaluate the therapy's effectiveness. This development highlights the potential of gene therapy in treating AMD.
Price reaction · baseline $26.245 (2024-02-08T15:24:00.000Z) · hit during market hours · 1 other FDMT headline(s) in the window, move may be shared
The therapy targets wet age-related macular degeneration effectively.
Plans for pivotal studies indicate confidence in the therapy's potential.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+128%
120-day peak, hindsight
Typical move
11.2%
average across 9 past catalysts
Cash runway
~18 mo
Low dilution risk
Lead asset
4D-150 IVT
Phase 3 · Macular Neovascularization Secondary to Age-Related Macular Degeneration
Full Press Release Details
Lei Lei Wu
News Reporter
4D Molecular Therapeutics said people with wet age-related macular degeneration (AMD) who received the company’s gene therapy as part of a clinical trial needed fewer …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Frequently Asked Questions
What condition does the gene therapy target?
The gene therapy targets wet age-related macular degeneration (AMD).
How does the therapy affect Eylea use?
Patients receiving the therapy reported needing fewer doses of Eylea.
What are the next steps for 4D Molecular Therapeutics?
The company plans to conduct pivotal studies to further evaluate the therapy.